Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
PSMA-targeted radiopharmaceutical therapy is an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, response rates and duration using 177Lu-PSMA-617 vary considerably between patients. Quantitative 177Lu SPECT imaging is one approach that may be leverag...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2023-12-01
|
| Serie: | Frontiers in Nuclear Medicine |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fnume.2023.1291253/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|